Immunocore to present at the 43rd Annual J.P. Morgan Healthcare Conference
Immunocore Holdings plc (Nasdaq: IMCR) has announced its upcoming participation in the 43rd Annual J.P. Morgan Healthcare Conference in San Francisco, California. The company, which specializes in developing transformative immunomodulating medicines for cancer, infectious diseases, and autoimmune diseases, will deliver a presentation on Wednesday, January 15, 2025, at 8:15 a.m. PST.
The presentation will be accessible through a live webcast on the 'Events & Presentations' section of Immunocore's website under the 'Investors' tab. A replay of the presentation will be available for a time after the event.
Immunocore Holdings plc (Nasdaq: IMCR) ha annunciato la sua prossima partecipazione alla 43a Conferenza Annuale J.P. Morgan sulla Salute a San Francisco, California. L'azienda, specializzata nello sviluppo di farmaci immunomodulanti trasformativi per il cancro, le malattie infettive e le malattie autoimmuni, presenterà una relazione mercoledì 15 gennaio 2025, alle 8:15 PST.
La presentazione sarà accessibile tramite una trasmissione in diretta nella sezione 'Eventi & Presentazioni' del sito web di Immunocore, sotto la scheda 'Investitori'. Una registrazione della presentazione sarà disponibile per un certo periodo dopo l'evento.
Immunocore Holdings plc (Nasdaq: IMCR) ha anunciado su próxima participación en la 43ª Conferencia Anual de Salud J.P. Morgan en San Francisco, California. La compañía, especializada en el desarrollo de medicamentos inmunomoduladores transformadores para el cáncer, enfermedades infecciosas y enfermedades autoinmunes, realizará una presentación el miércoles 15 de enero de 2025, a las 8:15 a.m. PST.
La presentación será accesible a través de una transmisión en vivo en la sección 'Eventos y Presentaciones' del sitio web de Immunocore bajo la pestaña 'Inversores'. Una repetición de la presentación estará disponible por un tiempo después del evento.
Immunocore Holdings plc (Nasdaq: IMCR)은 캘리포니아 샌프란시스코에서 열리는 제43회 연례 J.P. 모건 헬스케어 컨퍼런스에 참여할 것이라고 발표했습니다. 암, 전염병 및 자가면역 질환을 위한 혁신적인 면역조절 약물을 개발하는 데 전문적인 이 회사는 2025년 1월 15일 수요일 오전 8시 15분 PST에 발표를 진행할 예정입니다.
발표는 Immunocore 웹사이트의 '투자자' 탭 아래 '이벤트 및 발표' 섹션을 통해 실시간 웹캐스트로 시청할 수 있습니다. 이벤트 후 일정 기간 동안 발표의 재생이 가능할 것입니다.
Immunocore Holdings plc (Nasdaq: IMCR) a annoncé sa prochaine participation à la 43e Conférence Annuelle J.P. Morgan sur la Santé à San Francisco, Californie. L'entreprise, spécialisée dans le développement de médicaments immunomodulateurs transformateurs pour le cancer, les maladies infectieuses et les maladies auto-immunes, fera une présentation le mercredi 15 janvier 2025, à 8h15 PST.
La présentation sera accessible via un webinaire en direct dans la section 'Événements & Présentations' du site d'Immunocore sous l'onglet 'Investisseurs'. Un enregistrement de la présentation sera disponible pendant un certain temps après l'événement.
Immunocore Holdings plc (Nasdaq: IMCR) hat seine bevorstehende Teilnahme an der 43. Jahreskonferenz von J.P. Morgan im Gesundheitswesen in San Francisco, Kalifornien, angekündigt. Das Unternehmen, das sich auf die Entwicklung transformierender immunmodulierender Medikamente für Krebs, Infektionskrankheiten und Autoimmunerkrankungen spezialisiert hat, wird am Mittwoch, den 15. Januar 2025, um 8:15 Uhr PST eine Präsentation halten.
Die Präsentation wird über einen Live-Webcast im Abschnitt 'Veranstaltungen & Präsentationen' der Immunocore-Website unter dem Tab 'Investoren' zugänglich sein. Eine Aufzeichnung der Präsentation wird eine Zeit lang nach der Veranstaltung verfügbar sein.
- None.
- None.
Immunocore to present at the 43rd Annual J.P. Morgan Healthcare Conference
(OXFORDSHIRE, England & CONSHOHOCKEN, Penn. & GAITHERSBURG, Md., US, 6 January 2025) Immunocore Holdings plc (Nasdaq: IMCR) (“Immunocore” or the “Company”), a commercial-stage biotechnology company pioneering and delivering transformative immunomodulating medicines to radically improve outcomes for patients with cancer, infectious diseases and autoimmune diseases, today announced that management will participate in in a presentation at the 43rd Annual J.P. Morgan Healthcare Conference in San Francisco, California.
The presentation is scheduled for Wednesday, January 15, 2025, at 8:15 a.m. Pacific Standard Time (PST).
The presentation will be webcast live and can be accessed by visiting ‘Events & Presentations’, under ‘Events’, via the ‘Investors’ section of Immunocore’s website at www.immunocore.com. Following the event, a replay of the presentation will be made available for a limited time.
About Immunocore
Immunocore is a commercial-stage biotechnology company pioneering the development of a novel class of TCR bispecific immunotherapies called ImmTAX – Immune mobilizing monoclonal TCRs Against X disease – designed to treat a broad range of diseases, including cancer, autoimmune, and infectious disease. Leveraging its proprietary, flexible, off-the-shelf ImmTAX platform, Immunocore is developing a deep pipeline in multiple therapeutic areas, including five clinical stage programs in oncology and infectious disease, advanced pre-clinical programs in autoimmune disease and multiple earlier pre-clinical programs. The Company’s most advanced oncology TCR therapeutic, KIMMTRAK has been approved for the treatment of HLA-A*02:01-positive adult patients with unresectable or metastatic uveal melanoma in the United States, European Union, Canada, Australia, and the United Kingdom.
Contact Information
Immunocore
Sébastien Desprez, Head of Communications
T: +44 (0) 7458030732
E: sebastien.desprez@immunocore.com
Follow on Twitter: @Immunocore
Investor Relations
Clayton Robertson, Head of Investor Relations
T: +1 (215) 384-4781
E: ir@immunocore.com
FAQ
When is Immunocore (IMCR) presenting at the 2025 J.P. Morgan Healthcare Conference?
How can investors watch Immunocore's (IMCR) J.P. Morgan Healthcare Conference presentation?
What therapeutic areas does Immunocore (IMCR) focus on?
Will there be a replay available of Immunocore's (IMCR) J.P. Morgan presentation?
